You are using a browser that is no longer supported for this website.
Please use the latest version of Chrome, Firefox, Edge or Safari.


Bleiweis et al.

Bleiweis et al. summarize in this single center retrospective study their experiences with the Berlin Heart EXCOR® VAD in 9 patients with single ventricle physiology.

The patients had a median weight of 4.0kg and a median length of 64 days of VAD support. 83% of patients bridged to transplant survived.


The authors come to the following conclusion:

“Pulsatile para-corporeal VAD as a bridge-to-transplant is a feasible option in supporting the failing stage-one single ventricle.”

“This small cohort has shown promise in utilizing a pulsatile paracorporeal ventricular assist device to bridge-to-transplant with positive outcomes.”


Read more about:




The use of EXCOR in patients with single ventricle physiology is not described in Berlin Heart's IFU of EXCOR sterile components. A separate labeling for EXCOR® Venous Cannula will be provided. This presentation describes data and investigator-initiated studies from centers who have decided to treat patients with single ventricle physiology using EXCOR.


The access to some or all shown products may be restricted by country-specific regulatory approvals. The use of EXCOR® VAD for adults, RVAD-support, Excor mobile and EXCOR® Active is not FDA-approved.